Goldman Sachs’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $164K | Sell |
|
|||||
|
2025
Q1 | $158K | Sell |
|
|||||
|
2024
Q4 | $193K | Buy |
|
|||||
|
2024
Q3 | $221K | Buy |
|
|||||
|
2024
Q2 | $164K | Buy |
|
|||||
|
2024
Q1 | $39.3K | Sell |
|
|||||
|
2023
Q4 | $40.8K | Buy |
|
|||||
|
2023
Q3 | $35.3K | Buy |
|
|||||
|
2023
Q2 | $37.4K | Sell |
|
|||||
|
2023
Q1 | $420K | Buy |
|
|||||
|
2022
Q4 | $16.5K | Sell |
|
|||||
|
2022
Q3 | $17K | Sell |
|
|||||
|
2022
Q2 | $127K | Sell |
|
|||||
|
2022
Q1 | $196K | Buy |
|
|||||
|
2021
Q4 | $242K | Buy |
|
|||||
|
2021
Q3 | $245K | Buy |
|
|||||
|
2021
Q2 | $38K | Sell |
|
|||||
|
2021
Q1 | $467K | Buy |
|
|||||
|
2020
Q3 | – | Sell |
|
|||||
|
2020
Q2 | $105K | Buy |
|
|||||
|
2020
Q1 | $54K | Sell |
|
|||||
|
2019
Q4 | $88K | Buy |
|
|||||
|
2019
Q3 | $44K | Buy |
|
|||||
|
2019
Q2 | $39K | Sell |
|
|||||
|
2019
Q1 | $56K | Sell |
|
|||||
|
2018
Q4 | $65K | Sell |
|
|||||
|
2018
Q3 | $148K | Sell |
|
|||||
|
2018
Q2 | $130K | Buy |
|
|||||
|
2018
Q1 | $104K | Buy |
|
|||||
|
2017
Q4 | $64K | Sell |
|
|||||
|
2017
Q3 | $116K | Buy |
|
|||||
|
2017
Q2 | $123K | Sell |
|
|||||
|
2017
Q1 | $330K | Buy |
|
|||||
|
2016
Q4 | $59K | Buy |
|
|||||
|
2016
Q3 | $60K | Sell |
|
|||||
|
2016
Q2 | $57K | Buy |
|
|||||
|
2016
Q1 | $43K | Buy |
|
|||||
|
2015
Q4 | – | Sell |
|
|||||
|
2015
Q3 | $36K | Sell |
|
|||||
|
2015
Q2 | $160K | Buy |
|
|||||
|
2015
Q1 | $67K | Sell |
|
|||||
|
2014
Q4 | $56K | Buy |
|
|||||
|
2014
Q3 | – | Sell |
|
|||||
|
2014
Q2 | $37K | Sell |
|
|||||
|
2014
Q1 | $227K | Buy |
|
|||||
|
2013
Q4 | $97K | Buy |
|
|||||
|
2013
Q3 | $74K | Buy |
|
|||||
|
2013
Q2 | $68K | Buy |
|